Patents by Inventor Christina Von Roemeling
Christina Von Roemeling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230310419Abstract: The present application provides methods and compositions for treating cancer, for example, renal cell carcinoma, melanoma, ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancer, and more particularly to using an inhibitor of a stearoyl-Coenzyme A desaturase 1 (SCD1) enzyme in combination with a checkpoint inhibitor to treat these disorders.Type: ApplicationFiled: January 26, 2023Publication date: October 5, 2023Applicant: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Christina Von Roemeling, Han W. Tun, Thomas R. Caulfield, Yon Son Betty Kim
-
Publication number: 20230227509Abstract: This document provides methods and materials involved in treating cancer. For example, methods and materials for using a BiPE that can include (a) one or more molecules having the ability to bind to a cancer cell (e.g., a human breast cancer cell), (b) an optional linker component, and (c) one or more molecules having the ability to bind to an antigen presenting cell (e.g., a human macrophage) to treat cancer are provided.Type: ApplicationFiled: December 16, 2022Publication date: July 20, 2023Inventors: Yon Son Betty Kim, Wen Jiang, Christina Von Roemeling
-
Patent number: 11596629Abstract: The present application provides methods and compositions for treating cancer, for example, renal cell carcinoma, melanoma, ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancer, and more particularly to using an inhibitor of a stearoyl-Coenzyme A desaturase 1 (SCD1) enzyme in combination with a checkpoint inhibitor to treat these disorders.Type: GrantFiled: February 28, 2018Date of Patent: March 7, 2023Assignee: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Christina Von Roemeling, Han W. Tun, Thomas R. Caulfield, Yon Son Kim
-
Patent number: 11555056Abstract: This document provides methods and materials involved in treating cancer. For example, methods and materials for using a BiPE that can include (a) one or more molecules having the ability to bind to a cancer cell (e.g., a human breast cancer cell), (b) an optional linker component, and (c) one or more molecules having the ability to bind to an antigen presenting cell (e.g., a human macrophage) to treat cancer are provided.Type: GrantFiled: April 26, 2018Date of Patent: January 17, 2023Assignees: Mayo Foundation for Medical Education and Research and Board of Regents, The University of Texas SystemInventors: Yon Son Betty Kim, Wen Jiang, Christina Von Roemeling
-
Publication number: 20220411389Abstract: This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.Type: ApplicationFiled: April 5, 2022Publication date: December 29, 2022Applicant: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Han W. Tun, Thomas R. Caulfield, Christina Von Roemeling, Laura Ann Marlow
-
Patent number: 11325892Abstract: This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.Type: GrantFiled: May 24, 2019Date of Patent: May 10, 2022Assignee: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Han W. Tun, Thomas R. Caulfield, Christina Von Roemeling, Laura Ann Marlow
-
Publication number: 20210094987Abstract: This document provides methods and materials involved in treating cancer. For example, methods and materials for using a BiPE that can include (a) one or more molecules having the ability to bind to a cancer cell (e.g., a human breast cancer cell), (b) an optional linker component, and (c) one or more molecules having the ability to bind to an antigen presenting cell (e.g., a human macrophage) to treat cancer are provided.Type: ApplicationFiled: April 26, 2018Publication date: April 1, 2021Inventors: Yon Son Betty Kim, Wen Jiang, Christina Von Roemeling
-
Publication number: 20200061055Abstract: The present application provides methods and compositions for treating cancer, for example, renal cell carcinoma, melanoma, ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancer, and more particularly to using an inhibitor of a stearoyl-Coenzyme A desaturase 1 (SCD1) enzyme in combination with a checkpoint inhibitor to treat these disorders.Type: ApplicationFiled: February 28, 2018Publication date: February 27, 2020Applicant: Mayo Foundation for Medical Education and ResearchInventors: Christina Von Roemeling, Han W. Tun, John A. Copland, III, Thomas R. Caulfield, Yon Son Betty Kim
-
Publication number: 20190345123Abstract: This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.Type: ApplicationFiled: May 24, 2019Publication date: November 14, 2019Applicant: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Han W. Tun, Thomas R. Caulfield, Christina Von Roemeling, Laura Ann Marlow
-
Patent number: 10301273Abstract: This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.Type: GrantFiled: August 7, 2015Date of Patent: May 28, 2019Assignee: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Han W. Tun, Thomas R. Caulfield, Christina Von Roemeling, Laura Ann Marlow
-
Patent number: 10160972Abstract: This document provides methods and materials for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, methods and material for using one or more inhibitors of an SCD1 polypeptide to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)) or to increase the efficacy of a renal cell carcinoma treatment are provided. In addition, this document provides methods and materials for using elevated SCD1 expression levels in diseased tissues as an indication that an SCD1 inhibitor can be used as an appropriate therapeutic to ameliorate the disease.Type: GrantFiled: August 31, 2017Date of Patent: December 25, 2018Assignee: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Laura Ann Marlow, Christina Von Roemeling
-
Publication number: 20170362595Abstract: This document provides methods and materials for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, methods and material for using one or more inhibitors of an SCD1 polypeptide to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)) or to increase the efficacy of a renal cell carcinoma treatment are provided. In addition, this document provides methods and materials for using elevated SCD1 expression levels in diseased tissues as an indication that an SCD1 inhibitor can be used as an appropriate therapeutic to ameliorate the disease.Type: ApplicationFiled: August 31, 2017Publication date: December 21, 2017Applicant: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Laura Ann Marlow, Christina Von Roemeling
-
Publication number: 20170226073Abstract: This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.Type: ApplicationFiled: August 7, 2015Publication date: August 10, 2017Applicant: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Han W. Tun, Thomas R. Caulfield, Christina Von Roemeling, Laura Ann Marlow
-
Publication number: 20160152986Abstract: This document provides methods and materials for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, methods and material for using one or more inhibitors of an SCD1 polypeptide to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)) or to increase the efficacy of a renal cell carcinoma treatment are provided. In addition, this document provides methods and materials for using elevated SCD1 expression levels in diseased tissues as an indication that an SCD1 inhibitor can be used as an appropriate therapeutic to ameliorate the disease.Type: ApplicationFiled: December 7, 2015Publication date: June 2, 2016Inventors: John A. Copland, III, Laura Ann Marlow, Christina Von Roemeling
-
Patent number: 9233102Abstract: This document provides methods and materials for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, methods and material for using one or more inhibitors of an SCD1 polypeptide to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)) or to increase the efficacy of a renal cell carcinoma treatment are provided. In addition, this document provides methods and materials for using elevated SCD1 expression levels in diseased tissues as an indication that an SCD1 inhibitor can be used as an appropriate therapeutic to ameliorate the disease.Type: GrantFiled: March 7, 2013Date of Patent: January 12, 2016Assignee: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Laura Ann Marlow, Christina Von Roemeling
-
Publication number: 20150045418Abstract: This document provides methods and materials for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, methods and material for using one or more inhibitors of an SCD1 polypeptide to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)) or to increase the efficacy of a renal cell carcinoma treatment are provided. In addition, this document provides methods and materials for using elevated SCD1 expression levels in diseased tissues as an indication that an SCD1 inhibitor can be used as an appropriate therapeutic to ameliorate the disease.Type: ApplicationFiled: March 7, 2013Publication date: February 12, 2015Inventors: John A. Copland, III, Laura Ann Marlow, Christina Von Roemeling